title: Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.
abstract: The ligand-activated nuclear receptor pregnane X receptor (PXR) is known to play a role in the regulated expression of drug metabolizing enzymes and transporters. Recent studies suggest a potential clinically relevant role of PXR in breast cancer. However, the relevant pathway or target genes of PXR in breast cancer biology and progression have not yet been fully clarified. In this study, we show that mRNA expression of organic anion transporter polypeptide 1A2 (OATP1A2), a transporter capable of mediating the cellular uptake of estrogen metabolites, is nearly 10-fold greater in breast cancer compared with adjacent healthy breast tissues. Immunohistochemistry revealed exclusive expression of OATP1A2 in breast cancer tissue. Interestingly, treatment of breast cancer cells in vitro with the PXR agonist rifampin induced OATP1A2 expression in a time-dependent and concentration-dependent manner. Consistent with its role as a hormone uptake transporter, induction of OATP1A2 was associated with increased uptake of estrone 3-sulfate. The rifampin response was abrogated after small interfering RNA targeting of PXR. We then identified a PXR response element in the human OATP1A2 promoter, located approximately 5.7 kb upstream of the transcription initiation site. The specificity of PXR-OATP1A2 promoter interaction was confirmed using chromatin immunoprecipitation. Importantly, we used a novel potent and specific antagonist of PXR (A-792611) to show the reversal of the rifampin effect on the cellular uptake of E(1)S. These data provide important new insights into the interplay between a xenobiotic nuclear receptor PXR and OATP1A2 that could contribute to the pathogenesis of breast cancer and may also prove to be heretofore unrecognized targets for breast cancer treatment.
authors.affiliation: Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, Canada.
authors.forename: Henriette E
authors.initials: HE
authors.lastname: Meyer zu Schwabedissen
authors.forename: Rommel G
authors.initials: RG
authors.lastname: Tirona
authors.forename: Cindy S
authors.initials: CS
authors.lastname: Yip
authors.forename: Richard H
authors.initials: RH
authors.lastname: Ho
authors.forename: Richard B
authors.initials: RB
authors.lastname: Kim
mesh_terms: D001940:Breast / Q000737:chemistry; D001943:Breast Neoplasms / Q000209:etiology* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D047369:Chromatin Immunoprecipitation; D000090702:Constitutive Androstane Receptor; D004151:Dipeptides / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology*; D004970:Estrone / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D027361:Organic Anion Transporters / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D000077297:Pregnane X Receptor; D011401:Promoter Regions, Genetic; D011725:Pyridines / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D011960:Receptors, Estrogen / Q000502:physiology; D011987:Receptors, Steroid / Q000032:analysis / Q000502:physiology*; D012293:Rifampin / Q000494:pharmacology; D014157:Transcription Factors / Q000502:physiology
chemical_list: D000090702:Constitutive Androstane Receptor; D004151:Dipeptides; D004967:Estrogens; D027361:Organic Anion Transporters; D000077297:Pregnane X Receptor; D011725:Pyridines; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D011960:Receptors, Estrogen; D011987:Receptors, Steroid; C512988:SLCO1A2 protein, human; D014157:Transcription Factors; C520593:methyl 1-(5-(2-(3-benzyl-2-oxoimidazolidin-1-yl)-3,3-dimethylbutanamido)-4-hydroxy-6-phenyl-1-(4-(pyridin-2-yl)phenyl)hexan-2-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate; D004970:Estrone; C017296:estrone sulfate; D012293:Rifampin